Navigation Links
FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
Date:5/21/2008

>

Clinical Data

The sNDA submission is based on results of a multi-center, randomized, double-blind study in 699 adult patients, which demonstrated less procedural pain associated with blood draws or IV cannulations in those treated with Zingo compared to placebo. Of the study participants, 348 patients received placebo and 345 received Zingo one to three minutes before undergoing medical procedures requiring venipuncture or IV line placement at the back of hand or antecubital fossa (crux of the elbow). The primary endpoint was pain upon needle insertion, utilizing the VAS pain scale. The mean pain score in the Zingo-treated patients was significantly lower than in the placebo group (p = 0.003).

All three prespecified secondary efficacy endpoints also significantly favored Zingo over sham placebo: (1) the proportion of subjects who were pain-free (p < 0.0001); (2) the proportion of responders (p = 0.0005); and (3) the difference between pain experienced during the current (study) venous procedure compared with the recollection of pain experienced during a prior (historical) venous procedure (p = 0.0002).

There was also significantly greater subject satisfaction following use of Zingo compared with sham placebo on additional clinical outcome assessments: (1) satisfaction with overall performance of the device (p = 0.0013); (2) numbing from the device (p < 0.0001); and (3) desire to use the same treatment device again in the future (p = 0.0046).

Demographic characteristics and sites of administration were evenly distributed across treatment groups. Zingo was found to be well tolerated in this patient population. The most common skin assessment findings were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. The incidence of adverse events with Zingo was no higher than with placebo.

About Zingo

Zingo is an easy-to-administer, single-use, needle-free system that delivers sterile lidoca
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
11. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
(Date:5/1/2015)... , May 1, 2015 ... "Antibody Production Market by Product (Equipment, Consumables), by Type ... Companies, Diagnostic Labs, Research Institutes) - Analysis & ... report studies the global Antibody Production Market for ... market is expected to reach $2.572 Billion by ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... SANTA CLARA, Calif., March 20 Finesse Solutions, LLC, ... process,applications, is pleased to announce the opening of their ... this new E-Store at,Interphex in Philadelphia. The new E-Store ... ) so that customers can harness the power,of the ...
... March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... leading, fully integrated,biotechnology company focused on researching, ... China, announced today,that its board of directors ... The board has authorized 3SBio to purchase ...
... Mass., March 19 AdvanDx announced it ... the Year Award in the,field of rapid ... hospitals depend on AdvanDx,s easy-to-use, molecular-based,PNA FISH(TM) ... hours,instead of days. The rapid PNA FISH ...
Cached Biology Technology:3SBio Inc. Approves Share Repurchase Program 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 3AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 4
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... MA. Wed. March 6, 2013 New work from ... Hospital, Harvard University, MIT, and Yale University expands the ... known as a T helper 17 or Th17 cell ... of immune responses. By figuring out how these cells ...
... JOLLA, CA Scientists at the Salk Institute for ... only allow plants to adapt to various environments, but could ... Published March 6 in Nature , the findings ... throughout the world, their epigenomic makeup is as varied as ...
... All too often, stress turns addiction recovery into ... scientists with insight that might allow them develop a ... Neuron pinpoints the neural basis for stress-related ... advance could accelerate progress toward a medicine that prevents ...
Cached Biology News:Circuitry of cells involved in immunity, autoimmune diseases exposed 2Circuitry of cells involved in immunity, autoimmune diseases exposed 3Circuitry of cells involved in immunity, autoimmune diseases exposed 4Circuitry of cells involved in immunity, autoimmune diseases exposed 5Hidden layer of genome unveils how plants may adapt to environments throughout the world 2Hidden layer of genome unveils how plants may adapt to environments throughout the world 3Study pinpoints, prevents stress-induced drug relapse in rats 2Study pinpoints, prevents stress-induced drug relapse in rats 3
... Cytomics FC 500 Series is ... with the most advanced technologies ... delivers flexible testing, powerful software ... that help researchers optimize their ...
... KineticScan™ Reader is Cellomics‘ latest ... for Cell-based Screening". The KineticScan ... to do both temporal and ... processes, dynamic distribution and activity ...
... Protein/antibody delivery using PULSin may be superior ... example, unlike traditional transfection, with PULSin you ... level and time course of proteins in ... provide more information than traditional RNA interference ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
Biology Products: